Virus, immunosuppression, and the kidney transplant recipient;Virus, inmunosupresión y el receptor de trasplante renal

Revista de Investigacion Clinica

Volumn 57, Issue 4, 2005, Pages 582-595

  Alberú, Josefina ^a   Villasís, Angelina ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ACEPROMAZINE; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; AZATHIOPRINE; BASILIXIMAB; CEFTRIAXONE; CIDOFOVIR; CLARITHROMYCIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; DOXORUBICIN; GANCICLOVIR; IMIPENEM; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERFERON; INTERLEUKIN 10; LEFLUNOMIDE; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; OKT 3; PREDNISONE; RAPAMYCIN; RITUXIMAB; THYMOCYTE ANTIBODY; UNINDEXED DRUG; VANCOMYCIN; VINCRISTINE;

ADULT; ARTICLE; BK VIRUS; CASE REPORT; CLINICAL FEATURE; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; HUMAN; HUMAN TISSUE; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL NEPHRITIS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MALE; NEPHRECTOMY; POSTOPERATIVE INFECTION; VIRUS INFECTION;

ADULT; BK VIRUS; CHOLECYSTECTOMY, LAPAROSCOPIC; CHOLELITHIASIS; EPSTEIN-BARR VIRUS INFECTIONS; GANCICLOVIR; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; HYPERTENSION, RENOVASCULAR; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; KIDNEY NEOPLASMS; KIDNEY TRANSPLANTATION; LYMPHOMA, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; MALE; NEPHRECTOMY; NEPHRITIS; POLYOMAVIRUS INFECTIONS; POSTOPERATIVE COMPLICATIONS; RENAL DIALYSIS; REOPERATION; TUMOR VIRUS INFECTIONS; VIRAL LOAD;

EID: 27844443610     PISSN: 00348376     EISSN: 00348376     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741-51.
2. Frizzera G, Hanto DW, Gajl-Peczalska KJ, et al. Polymorphic difusse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 1981; 41: 4262.
3. Penn I. Cancers in cyclosporine-treated vs. azathioprine-treated patients. Transplant Proc 1996; 28: 876-78.
4. Le Meur Y, Potelune N, Jaccard A, et al. Lymphoproliferative syndromes after renal transplantation. Nephrologie 1998; 19: 255-61.
5. Rojas G, Alberú J, Bordes-Aznar J, et al. Clinical and pathological characterization of posttransplantation lymphoproliferative disorders in kidney transplant recipients: Single institution experience. Transplant Proc 1996; 28: 3319-22.
6. Ho M, Jaffe R, Miller G, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome alter transplantation and its manifestations in children. Transplantation 1988; 45: 719.
7. Shapiro R, Nalesnik M, McCauley J, et al. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant recipients receiving tacrolimus-based immunosuppression. Transplantation 1999; 68: 1851.
8. Miller G. Epstein-Barr virus -biology, pathogenesis and medical aspects. In: Fields BN, Knipe DM (Eds.). Virology, 2nd ed. New York: Raven Press Ltd; 1990, p. 1921-58.
9. Thorley-Lawson DA: Immunological responses to Epstein-Barr virus infection and the pathogenesis of EBV-induced diseases. Biochim Biophys Acta 1988; 948: 263-86.
10. Cleary ML, Nalesnik MA, Shearer WT, et al. Blood 1988; 72: 349.
11. Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplant lymphoproliferative disorders. Blood 1995; 85: 522-65.
12. Cesarman E, Chadburn A, Liu YF, et al. BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome. Blood 1998; 92: 2294.
13. Snow AL, Krams SM, Martinez OM. Epstein-Barr virus can protect latently infected B cell lymphomas from FASL/TRAIL-induced apoptosis. Am J Transplant 2004; 4(Suppl. 8): 511, abst 1289.
14. Winkelhorst JT, Brokelman WJ, Tiggeler RG, Wobbes T. Incidence and clinical course of de-novo malignancies in renal allograft recipients. Eur J Surg Oncol 2001; 27: 409-13.
15. Ondrus D, Pribylincova V, Breza J, et al. The incidence of tumours in renal transplant recipients with long-term immunosuppressive therapy. Int Urol Nephrol 1999; 31: 417-22.
16. Mihalov ML, Gattuso P, Abraham K, et al. Incidence of posttransplant malignancy among 674 solid-organ-transplant recipients at a single center. Clin Transplant 1996; 10: 248-55.
17. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increase incidence of lymphoproliferative disorders after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323:1723-8.
18. Cockfield SM, Preiksaitis J, Harvey E, et al. Is sequential use of ALG and OKT3 in renal transplant associated with an increase incidence of fulminant post-transplant lymphoproliferative disorder? Transplant Proc 1991; 23: 1473-6.
19. Bustami RT, Ojo AO, Wolfe RA, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004; 4: 87-93.
20. Penn I. The changing pattern of posttransplant malignancies. Transplant Proc 1991; 23: 1101-3.
21. Posey LA, Kerschner JE, Conley SF. Posttransplantation lymphoproliferative disease in children: otolaryngologic manifestations and management. South Med J 1999; 92: 1079-82.
22. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders ocurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988; 133: 173-92.
23. Hanto DW. Classification of Epstein-Barr virus associated posttransplant lymphoproliferative diseases: Implications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med 1995; 46: 381-94.
24. Frizzera G, Hanto DW, Gajl-Peczalska KJ, et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 1981; 41: 4262-79.
25. Tsai DE, Neary M, Hardy CL, et al. Use of EBV PCR for the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patients. Am J Transplant 2002; 2: 946-54.
26. Hanto DW, Gajl-Peczalska KJ, Frizzera G, et al. Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases ocurring after renal transplantation. Clinical, pathologic, and virologic findings and implications for therapy. Ann Surg 1983; 198: 356-68.
27. Nalesnik MA, Makowka L, Starzl TE. The diagnosis and treatment of post-transplant lymphoproliferative disorders. Curr Prob Surg 1988: 25: 371.
28. Green M, Michael MG, Weber SA, Rowe D, Reyes J. The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients. Pediatr Transplantat 1999; 3: 271-81.
29. Davis CL. The antiviral prophylaxis of post-transplant lymphoproliferative disorder. Springer Semin Immunopathol 1998; 20: 437-53.
30. Green M. Management of Epstein-Barr virus-induced posttransplant lymphoproliferative disease in recipients of solid organ transplantation. Am J Transplant 2001; 1: 103-108.
31. Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorders: a retrospective analysis of 32 patients. Ann Oncol 2000; 11(Suppl. 1): 113-16.
32. Comoli P, Maccario R, Valente U, et al. EBV- related PTLD alter kidney transplantation: Succesful treatment with a tailored regimen including autologous EBV-specific cytotoxic T lymphocytes. Am J Transplant 2004; 4(Suppl. 8): 250, abst 339.
33. Metes D, Storkus W, Zeevi A, et al. Ex vivo generation of effective Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocytes from the peripheral blood of immunocompetent Epstein-Barr virus seronegative individuals. Transplantation 2000; 70: 1507-15.
34. Buell JF, Gross TG, Beebe TM, et al. Analysis of chemotherapeutic regimens for the management of PTLD. Am J Transplant 2004; 4(Suppl. 8): 187, abst 138.
35. Karras A, Thervet E, Le Meur Y, et al. Succesful renal retransplantation after post-transplant lymphoproliferative disease. Am J Transplant 2004; 4: 1904-9.
36. Gardner SD, Field AM, Coleman DV, Hulme B. New human papovavirus (BK) isolated from urine after transplantation. Lancet 1971; 1: 1253-7.
37. Shah KV, Daniel R, Warszawski R. High prevalence of antibodies to BK virus, an SV40-related papovavirus, in residents of Maryland. J Infect Dis 1973; 128: 784-8.
38. Knowles WA. The epidemiology of BK Virus and the occurrence of antigenic and genomic subtypes. In: Khalili K, Stoner GL, eds. Human polyomaviruses: molecular and clinical perspectives. New York: Wiley-Liss; 2001, p. 527-59
39. Ling PD, Lednicky JA, Keitel WA, et al. The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: a 14-month longitudinal study. J Infect Dis 2003; 187: 1571-80.
40. Gardner SD, Mackenzie EF, Smith C, Porter AA. Prospective study of the human polyomaviruses BK and JC and cytomegalovirus in renal transplant recipients. J Clin Pathol 1984; 37: 578-86
41. Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002; 347: 488-96.
42. Coleman DV, Mackenzie EF, Gardner SD, Poulding JM, Amer B, Russell WJ. Human polyomavirus (BK) infection and ureteric stenosis in renal allograft recipients. J Clin Pathol 1978; 31: 338-47.
43. Binet I, Nickeleit V, Hirsch HH, et al. Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss. Transplantation 1999; 67: 918-22.
44. Randhawa PS, Finkelstein S, Scantlebury V, et al. Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation 1999; 67:103.
45. Hirsch HH, Mohaupt M, Klimkait T. Prospective monitoring of BK virus load after discontinuing sirolimus treatment in a renal transplant patient with BK virus allograft nephropathy. J Infect Dis 2001; 184: 1494-5.
46. Trofe J, Cavallo T, First M, et al. Polyomavirus in kidney and kidney-pancreas transplantation: a defined protocol for immunosuppression reduction and histologic monitoring. Transplant Proc 2002; 34: 1788.
47. Mengel M, Marwedel M, Radermacher J, et al. Incidence of polyomavirus-nephropathy in renal allografts: influence of modern immunosuppressive drugs. Nephrol Dial Transplant 2003; 18: 1190-6.
48. Trofe J, Roy-Chaudhury P, Gordon J, et al. Early steroid cessation/avoidance regimens are associated with a lower incidence of polyomavirus nephropathy compared to steroid based immunosuppression in kidney transplant recipients. Program and abstracts of American Transplant Congress 2003: The Fourth Joint American Transplant Meeting; May-June 4, 2003; Washington, DC. Abstract 856.
49. Shah KV. Human polyomavirus BKV and renal disease. Nephrol Dial Transplant 2000; 15: 754-5.
50. Ramos E, Drachenberg CB, Papadimitriou JC, et al. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 2002; 13: 2145-51.
51. Moens U, Subramaniam N, Johansen B, Johansen T, Traavik T. A steroid hormone response unit in the late leader of the noncoding control region of the human polyomavirus BK confers enhanced host cell permissivity. J Virol 1994; 68: 2398-408.
52. Buehrig CK, Hamad A, Kreps MA, et al. Graft outcomes in polyomavirus-associated nephropathy - The influence of surveillance biopsy and conversion to cyclosporine. Program and abstracts of American Transplant Congress 2003: The Fourth Joint American Transplant Meeting; May 30-June 4, 2003; Washington, DC. Abstract 849.
53. Nickeleit V, Klimkait T, Binet IF, et al. Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl J Med 2000; 342: 1309-15.
54. Drachenberg CB, Hirsch HH, Papadimitriou JC, Wali R, Bourquin PM, Ramos E. Quantitative measurements of BK viral load in plasma correlates with urine cytology and presence of BK nephropathy. Am J Transplant 2003; 5: 371.
55. Agha I, Alvaraz A, Lopez-Rocafort L, et al. A prospective evaluation of BK virus infection in renal transplant patients. Am J Transplant 2002; 2: 260.
56. Colvin RB, Mauiyyedi S. Differential diagnosis between infection and rejection in renal allografts. Transplant Proc 2001; 33: 1778-9.
57. Mylonakis E, Goes N, Rubin RH, Cosimi AB, Colvin RB, Fishman JA. BK virus in solid organ transplant recipients: an emerging syndrome. Transplantation 2001; 72: 1587-92.
58. Barri YM, Ahmad I, Ketel BL, et al. Polyoma viral infection in renal transplantation: the role of immunosuppressive therapy. Clin Transplant 2001; 15: 240-6.
59. Cibrik DM, O'Toole JF, Norman SP, et al. IVIG for the treatment of transplant BK nephropathy. Program and abstracts of American Transplant Congress 2003: The Fourth Joint American Transplant Meeting; May 30-June 4, 2003; Washington, DC. Abstract 850.
60. Wali R, Drachenberg CB, Hirsch HH, et al. Early detection of BK virus-associated nephropathy in renal allograft recipients and modification of immunosuppressive therapy to combinations with sirolimus and prednisone is associated with a reduction in BK viremia and improvement of allograft function. Am J Transplant 2003; 3: 371.
61. Poduval RD, Kadambi PV, Javaid B, et al. Leflunomide: a potential new therapeutic agent for BK nephropathy. Am J Transplantation 2003; 3: 189.
62. Kadambi PV, Josephson MA, Williams J, et al. Treatment of refractory BK virus-associated nephropathy with cidofovir. Am J Transplant 2003; 3: 186-91.
63. Mayr M, Nickeleit V, Hirsch HH, Dickenmann M, Mihatsch MJ, Steiger J. Polyomavirus BK nephropathy in a kidney transplant recipient: critical issues of diagnosis and management. Am J Kidney Dis 2001; 38: 13E.
64. Ramos E, Vincenti F, Lu WX, et al. Retransplantation in patients with graft loss caused by polyoma virus nephropathy. Transplantation 2004; 77(1): 131-3.
65. Petrogiannis-Haliotis T, Sakoulas G, Kirby J, et al. BK-related polyomavirus vasculopathy in a renaltransplant recipient. N Engl J Med 2001; 345: 1250-5.
66. Cubukcu-Dimopulo O, Greco A, Kumar A, Karluk D, Mittal K, Jagirdar J. BK virus infection in AIDS. Am J Surg Pathol 2000; 24: 145-9.
67. Peinemann F, de Villiers EM, Dorries K, Adams O, Vogeli TA, Burdach S. Clinical course and treatment of haemorrhagic cystitis associated with BK type of human polyomavirus in nine paediatric recipients of allogeneic bone marrow transplants. Eur J Pediatr 2000; 159: 182-8.
68. Hirsch H, Steiger J. Polyomavirus BK. Lancet Infect Dis 2003; 3: 611-23.
69. Moore KW, Russet F, Banchereau J. Evolving principles in immunopathology: interleukin 10 and its relationship to Epstein-Barr virus protein BCRF1. Semin Immunopathol 1991; 13: 157-66.
70. Birkeland SA, Bendtzen K. Interleukin-10 and Epstein-Barr Virus induced post transplant lymphoproliferative disorder. Transplantation 1996; 61: 1425-6.
71. Birkeland SA, Bendtzen K, Moller B, Hamilton-Dutoit S, Andersen HK. Interleukin-10 and posttransplant lymphoproliferative disorder after kidney transplantation. Transplantation 1999; 67: 876-81.
72. Bendtzen K. Cytokines and natural regulators of cytokines. Immunol Lett 1994; 43: 111-23.
73. Cherik WS, Kauffmaan HM, McBride MA et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003; 76: 1289-93.